SCHEDULE 13G/A: Vanguard Group Discloses 8.05% Stake in Kymera Therapeutics Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting an 8.05% beneficial ownership stake in Kymera Therapeutics Inc. as of March 31, 2025.

Summary

• The Vanguard Group, a Pennsylvania-based investment adviser, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Kymera Therapeutics Inc.
• As of March 31, 2025, The Vanguard Group beneficially owns an aggregate of 5,231,392 shares of Kymera Therapeutics Inc. Common Stock.
• This ownership represents 8.05% of the class of securities.
• The Vanguard Group holds sole voting power over 0 shares, shared voting power over 52,531 shares, sole dispositive power over 5,126,504 shares, and shared dispositive power over 104,888 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership, with no explicit positive or negative financial or operational news about the issuer. The presence of a large institutional investor can be viewed as a neutral to slightly positive signal.

Positives

• The disclosure of a significant 8.05% beneficial ownership by a major institutional investor like The Vanguard Group can be interpreted by the market as a vote of confidence in Kymera Therapeutics Inc.

Negatives

• The document does not contain any information that would be considered negative for Kymera Therapeutics Inc.

Risks

• The document does not explicitly mention any specific risks related to Kymera Therapeutics Inc. or its operations.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Kymera Therapeutics Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Ashley Grim, Head of Global Fund Administration, The Vanguard Group)

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific analysis of broader industry trends or competitive landscape for Kymera Therapeutics Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor sentiment and perception of stability.
• Management: Awareness of a large institutional holder may influence strategic decisions, though Vanguard's filing states no intent to influence control.

Next Steps

• The Vanguard Group will continue to file amendments to this Schedule 13G as required by SEC regulations if there are material changes to its beneficial ownership in Kymera Therapeutics Inc.

Key Dates

Keywords

Kymera Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional investor, common stock, SEC filing, ownership disclosure